Radiotherapy Induced Oral Mucositis Treatment Market Report 2026

The radiotherapy induced oral mucositis treatment market size has grown strongly in recent years. It will grow from $1.85 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing use of radiotherapy for head and neck cancers, rising awareness of treatment side effects, availability of supportive oncology drugs, expansion of oncology care centers, growing involvement of dental specialists in cancer care.

The radiotherapy induced oral mucositis treatment market size is expected to see steady growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing adoption of advanced mucosal protection therapies, rising investments in supportive oncology research, growing demand for non-invasive pain management, expansion of hospital-based supportive care programs, increasing focus on early intervention strategies. Major trends in the forecast period include increasing development of targeted supportive care therapies, growing use of topical and device-based treatments, rising focus on patient quality of life management, expansion of preventive oral care protocols, enhanced integration of multidisciplinary cancer care.

The rising global prevalence of cancer is expected to propel the growth of the radiotherapy-induced oral mucositis treatment market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells that can invade surrounding tissues and organs, often resulting from genetic mutations influenced by environmental and lifestyle factors. The growing incidence of cancer worldwide is largely driven by factors such as an aging population, lifestyle behaviors including tobacco use, obesity, and alcohol consumption, as well as environmental factors such as air pollution. Radiotherapy-induced oral mucositis treatments support cancer patients by easing painful mucosal damage caused by radiotherapy, helping patients better tolerate treatment and maintain adequate nutrition, ultimately improving quality of life during cancer care. For instance, in August 2024, according to a report published by Macmillan Cancer Support, a UK-based charitable organization, more than 3 million people in the UK were living with cancer in 2024, with projections indicating this number will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing global prevalence of cancer is driving the growth of the radiotherapy-induced oral mucositis treatment market.

Major companies operating in the radiotherapy-induced oral mucositis treatment market are concentrating on developing innovative solutions, such as low-level laser therapy, to promote healing, reduce pain, and improve patient outcomes during cancer treatment. Low-level laser therapy, also known as cold laser therapy or photobiomodulation, is a non-invasive approach that uses low-power lasers or light-emitting diodes to stimulate tissue repair and reduce pain and inflammation. For instance, in October 2024, Jaguar Health Inc., a US-based pharmaceutical company, launched the prescription oral mucositis product Gelclair. The product is specifically designed to manage pain associated with oral mucositis, a condition affecting up to 90% of head and neck cancer patients undergoing chemotherapy and radiotherapy. By forming a protective coating over the oral mucosa, Gelclair delivers rapid and long-lasting pain relief without the stinging or numbing sensations commonly seen with other treatments.

In September 2024, InfuSystem Holdings Inc., a US-based healthcare services company, partnered with ChemoMouthpiece LLC. Through this partnership, InfuSystem aims to strengthen its oncology product portfolio by exclusively distributing the Chemo Mouthpiece in the United States, supporting the reduction of incidence and severity of oral mucositis among cancer patients receiving chemotherapy and radiotherapy. ChemoMouthpiece LLC is a US-based company that provides treatments for radiotherapy-induced oral mucositis.

Major companies operating in the radiotherapy induced oral mucositis treatment market are Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr Reddys Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A S, Glenmark Pharmaceuticals Ltd., Almirall S.A., Fagron Group BV, Sage Products LLC, Soligenix Inc., EUSA Pharma Ltd., Galera Therapeutics Inc., Enzychem Lifesciences Corp., Jaguar Health Inc., EpicentRx Inc., MONOPAR Therapeutics Inc., Solasia Pharma KK, Pfizer Inc., Novartis AG, Sanofi S.A., Merck And Co Inc., Bristol Myers Squibb Company, AstraZeneca PLC.

North America was the largest region in the radiotherapy induced oral mucositis treatment market in 2025. The regions covered in the radiotherapy induced oral mucositis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiotherapy induced oral mucositis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the radiotherapy-induced oral mucositis treatment market by increasing costs of imported pharmaceuticals, medical devices, topical formulations, and supportive care equipment. Hospitals and oncology centers in North America and Europe are most affected due to dependence on imported specialty drugs and devices, while Asia-Pacific faces pricing pressures on treatment accessibility. These tariffs are increasing therapy costs and impacting patient affordability. However, they are also encouraging local drug manufacturing, regional device production, and development of cost-effective supportive care solutions.

The radiotherapy induced oral mucositis treatment market research report is one of a series of new reports that provides radiotherapy induced oral mucositis treatment market statistics, including radiotherapy induced oral mucositis treatment industry global market size, regional shares, competitors with a radiotherapy induced oral mucositis treatment market share, detailed radiotherapy induced oral mucositis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy induced oral mucositis treatment industry. This radiotherapy induced oral mucositis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radiotherapy-induced oral mucositis treatment refers to the medical therapies and interventions used to manage and relieve oral mucositis, a painful condition resulting from radiotherapy. These treatments aim to reduce inflammation, prevent infections, alleviate pain, and support the healing of oral mucosal tissues damaged during cancer therapy, particularly among patients receiving radiotherapy for head and neck cancers.

The primary drug classes used in radiotherapy-induced oral mucositis treatment include antibiotics, antifungals, anti-inflammatory agents, and antineoplastic drugs. Antibiotics are administered to prevent or treat bacterial infections by eliminating bacteria or inhibiting their growth. Available treatment options include topical formulations, systemic medications, and medical devices. The radiotherapy modalities associated with this treatment include external beam radiation therapy, intensity-modulated radiation therapy, brachytherapy, proton therapy, stereotactic radiosurgery, and others. Severity is classified as mild, moderate, or severe oral mucositis. These treatments are provided across hospitals, oncology centers, research institutes, and dental clinics.

The radiotherapy-induced oral mucositis treatment market includes revenues earned by entities by providing services such as symptom management, cryotherapy, wound care and healing support, and pharmacological interventions and related products, including mouthwashes and rinses, topical gels and creams, oral sprays, and hydrogels and hydrating agents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.